Neoadjuvant Intravesical Therapy for Non–muscle-invasive Bladder Cancer: A New Approach for Old Agents?

Mostafid, Hugh

doi:10.1016/j.eururo.2020.07.026

Cited by 2 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found a 70.4% complete response after 14 days. Contrarily, Mostafied et al (13) evaluated 82 small LG-Ta-NMIBC patients. They only found 37% complete responses after four MMC instillations for one week.…”

Section: Chemoablation Of Nmibcmentioning

confidence: 99%

Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review

et al. 2022

View full text Add to dashboard Cite

Purpose: To describe the current scientifi c knowledge and clinical experience in low-grade-non-muscle-invasive bladder cancer (LG-NMIBC) patients in challenging scenarios. Materials and Methods: Medline, Embase, Google Scholar, and Cochrane Central were searched until March 2021. Results: A total of 841 studies were identifi ed, and abstracts were analyzed. Twentyone relevant studies were then identifi ed and reviewed. After all, information was gathered from 16 studies, the authors discussed the specifi c topics, and expert opinions were also included in the discussion. There have been some studies that can help us to have some insights on how to manage these patients. Very distinctive strategies have been reported in the literature, mainly anecdotally or in small randomized studies. Some of these treatments outlined in the present manuscript include repeated TURBTs, chemoablation, BCG immunoablation, partial cystectomy, radical cystectomy, radiotherapy, chemotherapy, and future perspectives. In the current manuscript, we have combined these strategies in a proposed algorithm. Conclusion: For those LG-NMIBC patients in challenging scenarios, we have found repeated TURBTs, chemoablation, BCG immunoablation, partial cystectomy, radical cystectomy, radiotherapy, and chemotherapy are attractive modalities to treat them effectively. Also, the current manuscript proposes an algorithm to overcome these challenges.

show abstract

Section: Chemoablation Of Nmibcmentioning

confidence: 99%

Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Therefore, a small number of medical centers have attempted to perform a single instillation of chemotherapy before removing the bladder during RC. The concept of neoadjuvant intravesical chemotherapy before resection of bladder cancer is promising and deserves further evaluation 13,14 . In phase I clinical study, the safety and efficacy of neoadjuvant intravesical therapy were investigated in patients who were scheduled for RC and not eligible for neoadjuvant chemotherapy 15 .…”

Section: Introductionmentioning

confidence: 99%

“…The concept of neoadjuvant intravesical chemotherapy before resection of bladder cancer is promising and deserves further evaluation. 13 , 14 In phase I clinical study, the safety and efficacy of neoadjuvant intravesical therapy were investigated in patients who were scheduled for RC and not eligible for neoadjuvant chemotherapy. 15 Within the next few years, perioperative intravesical therapy is set to become a future research priority for the treatment of bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors

Yang

Zhang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

To clarify the necessity and effect of a single intraoperative instillation of chemotherapy during radical cystectomy. Methods: Patients who underwent radical cystectomy for bladder cancer between January 2013 and April 2019 were retrospectively evaluated and divided into a non-instillation group and an instillation group according to the intraoperative instillation of chemotherapy. Univariate and multivariate Cox regression was used to determine the clinical predictors of overall survival and disease-free survival. Kaplan-Meier analysis and log-rank tests were performed to analyze overall survival and disease-free survival.Results: Of the 320 patients who were enrolled in the study, 113 underwent radical cystectomy with intraoperative instillation of chemotherapy. Univariate Cox analysis showed that intraoperative instillation was not a risk factor for overall survival or disease-free survival (HR: 1.04, 95% CI: 0.66-1.63, p = 0.864; HR:1.11, 95% CI: 0.76-1.62, p = 0.602, respectively). As shown in the Kaplan-Meier analysis, no significant differences were noted in overall survival (p = 0.857) and disease-free survival (p = 0.600) between the two groups. A subgroup analysis demonstrated that intraoperative instillation was not associated with a statistically better overall survival and disease-free survival in the nonmuscle invasive (p = 0.852 and 0.836) and muscle-invasive (p = 0.929 and 0.805) patients. Conclusion:A single intraoperative instillation of chemotherapy during radical cystectomy was not related to better disease-free survival or overall survival. It is

show abstract

Neoadjuvant Intravesical Therapy for Non–muscle-invasive Bladder Cancer: A New Approach for Old Agents?

Cited by 2 publications

References 8 publications

Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review

Challenging dilemmas of low grade, non-invasive bladder cancer: a narrative review

Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors

Contact Info

Product

Resources

About